<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653185</url>
  </required_header>
  <id_info>
    <org_study_id>01-06-TL-SYR-472-007</org_study_id>
    <secondary_id>U1111-1183-0302</secondary_id>
    <nct_id>NCT00653185</nct_id>
  </id_info>
  <brief_title>Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472,
      once daily (QD), in subjects with Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus is a complex metabolic disorder characterized by abnormal insulin
      secretion and glucose homeostasis, resulting from impaired pancreatic beta-cell function and
      insulin resistance in target tissues. The worldwide prevalence of type 2 diabetes mellitus is
      reaching epidemic proportions, and the total number of cases is expected to reach 221 million
      by 2010. The high incidence of the disease and its associated complications places a
      significant burden on healthcare systems.

      The primary risk factor for the development of type 2 diabetes mellitus is obesity and its
      associated insulin resistance. Insulin resistance is characterized by an impaired response to
      the physiologic effects of insulin and leads to decreased cellular glucose uptake, increased
      hepatic gluconeogenesis, and a compensatory increase in insulin secretion that contributes to
      beta-cell exhaustion. Therefore in the insulin-resistant state, blood glucose and insulin
      levels are increased. The relationship between improved glycemic control in patients with
      type 2 diabetes mellitus and the delay or prevention of comorbidities has been reported in
      the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes
      Study. Therefore, reduction of persistent hyperglycemia is the highest priority in treating
      this disease.

      Diet and exercise are important and effective measures for maintaining glycemic control in
      individuals with insulin resistance, impaired glucose tolerance, and type 2 diabetes
      mellitus, particularly in the early stages of disease progression. In cases where diet and
      exercise alone fail to adequately maintain glycemic control, oral antidiabetic drugs are
      typically used. Combination oral therapy and eventually insulin are usually required to
      maintain lower blood glucose levels but can result in adverse effects including hypoglycemia
      and weight gain. Therefore, novel safe and effective antidiabetic therapies are needed.

      Dipeptidyl peptidase-4 is a ubiquitous aminopeptidase that is widely expressed in many
      tissues; it is thought to be primarily responsible for the in vivo degradation of at least
      two gut-derived incretin hormones, namely glucagon-like peptide-1 and glucose-dependent
      insulinotropic peptide, which are both released in response to nutrient ingestion.
      Glucagon-like peptide-1 has been demonstrated to augment glucose-dependent insulin secretion;
      suppress glucagon release and hepatic gluconeogenesis; inhibit gastric emptying, and reduce
      appetite and food intake. Glucagon-like peptide-1 and glucose-dependent insulinotropic
      peptide also have been shown to promote insulin biosynthesis and stimulate beta cell
      proliferation and survival. Orally available inhibitors of dipeptidyl peptidase-4 activity
      have been developed that increase intact postprandial glucagon-like peptide-1 levels after
      oral administration.

      SYR-472 is a selective inhibitor of dipeptidyl peptidase-4 in development to improve glycemic
      control in patients with type 2 diabetes mellitus. The aim of this study is to evaluate
      SYR-472 in subjects with type 2 diabetes mellitus who have not previously achieved adequate
      glycemic control with lifestyle modification (diet/exercise) or metformin antidiabetic
      monotherapy. Study participation is anticipated to be up to 14 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin</measure>
    <time_frame>Weeks 12 or Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,5-Anhydroglucitol</measure>
    <time_frame>Weeks 2, 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proinsulin</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proinsulin/insulin ratio</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline C-peptide</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis model assessment of beta cell function</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis model assessment of insulin resistance</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rescue</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5%</measure>
    <time_frame>Week 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0%</measure>
    <time_frame>Week 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol)</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">369</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SYR-472 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYR-472 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYR-472 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYR-472 200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 25 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 50 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 100 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 200 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a historical diagnosis of type 2 diabetes mellitus.

          -  Has undergone less than 7 days of any antidiabetic therapy except lifestyle
             modification (diet/exercise) within 8 weeks prior to Screening; or has received
             metformin monotherapy for at least 8 weeks prior to Screening and maintained a stable
             daily dose of metformin for at least 12 weeks prior to randomization.

          -  The subject receiving metformin monotherapy at randomization must have been at least
             75% compliant with his or her regimen during the Run-in/Stabilization Period as
             determined by subject diary and investigator assessment.

          -  Has received no treatment with antidiabetic agents other than metformin within the 8
             weeks prior to Screening.

          -  Has a glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive, at
             Screening and at the Week -1 Visit.

          -  The subject's fasting C-peptide concentration is greater than or equal to 0.8 ng/mL.

          -  Has a fasting plasma glucose concentration less than 275 mg/dL.

          -  If regularly uses other non-excluded medications, must be on a stable dose for at
             least the 4 weeks prior to Screening.

          -  Has a systolic blood pressure reading less than 160 mm Hg and a diastolic pressure
             reading less than 100 mm Hg.

          -  Has a hemoglobin value greater than or equal to 12 g/dL for men and greater than or
             equal to 10 g/dL for women.

          -  Has an alanine aminotransferase level is less than or equal to 3 times the upper limit
             of normal.

          -  Males have a serum creatinine value less than 1.5 mg/dL; females have a serum
             creatinine value less than 1.4 mg/dL.

          -  Has a urine albumin/creatinine ratio less than 1000 Î¼g/mg.

          -  Has a thyroid-stimulating hormone level less than or equal to the upper limit of the
             normal range and is clinically euthyroid.

          -  Females must be not be pregnant or lactating, and must agree to use adequate
             contraception throughout the duration of the study.

          -  Is able and willing to monitor his or her own blood glucose concentrations with a home
             glucose monitor.

          -  Has no major illness or debility that in the investigator's opinion prohibits the
             subject from completing the study.

        Exclusion Criteria

          -  Is being concurrently treated with antidiabetic therapy other than metformin and
             lifestyle intervention.

          -  Has a history of cancer, other than squamous cell or basal cell carcinoma of the skin
             that has not been in full remission for at least 5 years prior to Screening.

          -  Has a history of laser treatment for proliferative diabetic retinopathy within the 6
             months prior to Screening.

          -  Has a history of treated diabetic gastric paresis.

          -  Has New York Heart Association class III or IV heart failure regardless of therapy.

          -  Has a history of coronary angioplasty, underwent coronary stent placement or coronary
             bypass surgery, or suffered a myocardial infarction, or stroke within the 6 months
             prior to Screening.

          -  Has a history of any hemoglobinopathy that may affect determination of glycosylated
             hemoglobin.

          -  Has a history of infection with human immunodeficiency virus.

          -  Has a history of a psychiatric disorder that in the investigator's opinion will affect
             the subject's ability to participate in the study.

          -  Has ingested or received systemically injected glucocorticoids within the 3 months
             prior to randomization. Inhaled corticosteroids are allowed.

          -  Has used prescription or over-the-counter weight-loss drugs within the 3 months prior
             to randomization.

          -  Has received any investigational drug within the 30 days prior to Screening or has
             received an investigational antidiabetic drug within the 3 months prior to Screening.

          -  Has received previous treatment in an investigational study of SYR-472.

          -  Has a known hypersensitivity to any compound related to SYR-472.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pell City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallassee</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sierra Vista</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dawsonville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taunton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsbluff</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sparta</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Central Point</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clemson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quetzaltenango</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sigulda</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kedainiai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alba Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bihor</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Satu Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <disposition_first_submitted>June 20, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 20, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 22, 2016</disposition_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

